News

Administrative claims database analysis revealed a lower AMD incidence in patients treated with JAK inhibitor therapy versus non–JAK-based immunotherapy.

Casey Schlacher discusses the FDA approval of the new weight-based oral solution, RINVOQ LQ (upadacitinib), for treating pediatric patients with arthritis, highlighting its importance for improving patient outcomes and quality of life.

A recent study shows the need to standardize sonography for asymptomatic hyperuricemia detection.

Test your knowledge of active oligoarthritis treatment recommendations from the 2021 ACR guideline on JIA with this quiz.

An observational study found patients with chronic inflammatory diseases who smoke may respond less to biologics than non-smokers.

Gerd Burmester, MD, discusses the favorable long-term safety data of upadacitinib treatment across rheumatic diseases.

A study revealed factors linked to gout flare risk included the absence of tophi, younger age, and more. Taking allopurinol over febuxostat or vice versa did not affect flare risk.

The study identified 6 key themes highlighting how gout impacts work life, including the severity of physical symptoms, the challenge of physically demanding jobs, and emotional and social experiences.

A survey shows females with PsA have a greater disease burden than males with PsA.

A study found patients with psoriasis and psoriatic arthritis had a polyneuropathy relative risk of 22.09. However, an analysis revealed the neuropathy risk was not significant.

Older children (aged >5 years) with JIA exhibited a 40% to 45% higher point prevalence of active disease at month 12 when compared with younger patients.

Fibromyalgia severity is correlated to how long the condition takes to get diagnosed, a new study showed.

Discontinuation was less likely in the prospective Patient Support Program (PSP) group compared with the retrospective non-PSP group.

The rheumatology month in review for June 2024 addresses the critical role of psychological, socioeconomic, and lifestyle factors in the management of rheumatic diseases, particularly rheumatoid arthritis and fibromyalgia.

The study demonstrated clinical similarity between the proposed biosimilar and the reference products.

A review of the 20 novel drugs approved by the US Food and Drug Administration during the first half of 2024, with links to coverage from MJH Life Sciences publications.

A study presented at EULAR 2024 found anxiety, depression, and sleep disorders were significantly correlated to pain intensity.

Patients with RA and obesity exhibited worse scores for subjective measures like pain and fatigue compared to those without obesity.

Administering canakinumab prophylaxis before a pegloticase infusion prevents new gout glares induced by pegloticase + methotrexate treatment.

RA was linked to an increased risk of ischemic and hemorrhagic strokes, with further analysis revealing sex-based differences in stroke outcomes in men vs women with RA.

A study presented at EULAR 2024 suggests tophaceous gout patients may benefit from a longer pegloticase treatment course alongside urate-lowering therapy.

A study presented at EULAR 2024 found patients with RA of low socioeconomic status have a high prevalence of fatigue.

Compared to patients on stable TNFi, patients tapering TNFi to withdrawal experienced significantly more flares and had lower Boolean 2.0 remission rates.

A study presented at EULAR 2024 found fibromyalgia and worse pain, symptom severity, and depression scores were linked to a risk of low medication adherence.

More than half of patients with RA or PsA without obesity exhibited steatosis despite having low disease activity, with no differences observed based on methotrexate use and dosage.

Positive personality traits and perceived disease impact may play a larger role in explaining sleep disturbances in patients with RA than disease activity, anxiety, or depression.

Patients with RA had a greater risk of delayed cervical cancer screening, and smoking was associated with a decrease in prostate cancer screening in patients with RA.

Presented at EULAR 2024, a study suggested controlling RA disease activity may be important from a psycho-social perspective.

Findings from a 2-year extension of the Plants for Joints randomized controlled trial show promise for the long-term benefits of diet, physical activity, and stress management in RA.

Phase 2 data presented at EULAR 2024 showed gout patients on febuxostat and ruzinurad were more likely to achieve the target serum uric acid level than those on febuxostat alone.